Leveraging Data Science to Elucidate Ligand Features for Pd-Catalyzed Enantioretentive -Arylations of Cyclic α-Substituted Amines in Aqueous Media.

Journal: Journal of the American Chemical Society
Published Date:

Abstract

The combination of high-throughput experimentation (HTE) and data science offers a promising solution for the optimization of challenging chemical reactions, although current data science approaches to deal with highly skewed data sets resulting from typical HTE campaigns are limited. One such attractive yet challenging reaction is the preparation of chiral tertiary anilines via palladium-catalyzed -arylation of enantioenriched, α-substituted secondary amines. While enantioenriched tertiary anilines are highly valuable motifs in medicinal chemistry, their synthesis remains challenging to accomplish in high yields and enantiospecificity. Herein, we disclose a method for the enantioretentive -arylation of cyclic secondary amines. After an extensive HTE campaign, a novel phosphorinane ligand for palladium, 'NiniPhos,' was found to demonstrate high yields (up to 96%) and enantiospecificity (96 to >99% es) across a range of amines with diverse aryl halides under aqueous conditions. Despite screening more than 120 ligands, only 31 demonstrated catalytic activity (>10% yield), resulting in a highly skewed data set. By applying data science-driven hotspot analysis and machine learning (linear support vector machines), the structural features of ligands leading to the activity cliff were identified, pinpointing di-butylphosphines and phosphorinanes as privileged ligand classes in this reaction. This workflow offers a generalizable strategy for extracting mechanistic insights from skewed data sets, which can be leveraged for reaction design and optimization.

Authors

  • Andrew R Ickes
    Process Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States.
  • Jordan P Liles
    Department of Chemical Engineering, MIT, Cambridge, Massachusetts 02139, United States.
  • Niginia Borlinghaus
    Small Molecule Therapeutics & Platform Technologies, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.
  • Jeremy Henle
    Process Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States.
  • Rafal Swiatowiec
    Process Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States.
  • Niharika Prakash Kaushik
    Department of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.
  • Wilfried M Braje
    Small Molecule Therapeutics & Platform Technologies, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.
  • Kaid C Harper
    Process Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States.
  • Shashank Shekhar
    Process Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States.
  • Matthew S Sigman
    Department of Chemistry, University of Utah 315 South 1400 East Salt Lake City Utah 84112 USA.

Keywords

No keywords available for this article.